At a glance

ClinicalIndex Comparison Record

N/ACompleted· 88 enrolled

Drug / intervention

Chemotherapy +2 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04882371

NCT04882371N/ACompleted

Compare CT.gov

Comparison of MRI With PET / CT in the Evaluation of Response to Neoadjuvant Therapy Based on the Molecular Subtypes of Breast Cancer

Cem Ilgin Erol·observational·Posted May 11, 2021·Updated May 11, 2021

In Brief

An observational study evaluating Chemotherapy, Magnetic Resonance Imaging (MRI), and 1 other intervention for Breast Cancer and Chemotherapy Effect. Completed, enrolled 88 participants across 1 site.

Detailed Summary

The current study aims to determine the diagnostic accuracy of Magnetic Resonance Imaging (MRI) and Positron Emission Tomography- Computed Tomography (PET-CT) in predicting a pathological response of molecular subtypes of breast cancer to neoadjuvant chemotherapy (NAC).

Study Details

Study Typeobservational

Allocation--

Masking--

Primary Purpose--

ConditionsBreast Cancer, Chemotherapy Effect

CountriesTurkey (Türkiye)

Collaborators--

Timeline

N/ACompletedFinished

201820192020202120222023202420252026

Enrollment StartJan 2018

Primary CompletionMay 2020

Study CompletionAug 2020

First PostedMay 2021

TodayJul 2026

First PostedMay 11, 2021

Enrollment StartJan 1, 2018

Primary CompletionMay 1, 2020

Study CompletionAug 1, 2020

TodayJul 2, 2026

Enrollment to primary: 2.3 yearsPosted 5.1 years ago

Interventions

Chemotherapydrug

Neoadjuvant Chemotherapy for Breast Cancer

Magnetic Resonance Imaging (MRI)other

Performed contrasted MRI for evaluate response of neoadjuvant chemotherapy

Positron emission tomography - Copmputer Tomography (PET-CT)other

Performed contrasted PET-CT for evaluate response of neoadjuvant chemotherapy